Brightsurf Science News & Current Events

March 31, 2012
2 targeted therapies act against Ewing's sarcoma tumors
A pair of targeted therapies shrank tumors in some patients with treatment-resistant Ewing's sarcoma or desmoplastic small-round-cell tumors, according to research led by investigators from the University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2012.

Commonly used diabetes drug may help to prevent primary liver cancer
Metformin, a drug widely used to treat Type 2 diabetes, may help to prevent primary liver cancer, researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center report in the April 2012 issue of Cancer Prevention Research.

Towards TB elimination: ECDC and ERS introduce new guidelines on tuberculosis care in Europe
Today, the European Respiratory Society and the European Center for Disease Prevention and Control publish their jointly developed European Union Standards for Tuberculosis Care.

Biomarker identified in relation to drug response in refractory urothelial cancer
The antiangiogenic drug pazopanib has demonstrated clinically meaningful activity in patients with refractory urothelial cancer, according to results presented at the AACR Annual Meeting 2012.

Early clinical data show galeterone safe, effective against prostate cancer
Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone, a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012.

Tokai Pharmaceuticals' galeterone well-tolerated in patients with advanced prostate cancer
Tokai Pharmaceuticals, Inc. announced that its lead candidate galeterone was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer in a Phase one study.

Metformin appeared to slow prostate cancer growth
The use of metformin in men with prostate cancer before prostatectomy helped to reduce certain metabolic parameters and slow the growth rate of the cancer, according to the results of a phase II study.

Oxygen in tumors predicts prostate cancer recurrence
Low oxygen levels in tumors can be used to predict cancer recurrence in men with intermediate-risk prostate cancer even before they receive radiation therapy. is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to